1.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
|
|
2.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0305091, WYETH-C-3066K1-304-WW, NCT00065468
|
|
3.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3066K1-305, UCLA-0502046-01A, WYETH-3066K1-305-WW, NCT00117598
|
|
4.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3066K1-404, B1771003, NCT00474786
|
|
5.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3066K1-3311, B1771006, NCT00631371
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-0101, NCT00022724, NABTC-01-01
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0452, NCI-6986, 6986, NCT00112840
|
|
8.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ABTC-0402 CDR0000429553, U01CA062399, ABTC-0402, NCI-06-C-0053, NABTC-04-02, NCT00112736
|
|
9.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ABTC-05-02 CDR0000476286, U01CA062399, ABTC-05-02, NABTC-05-02, NCT00335764
|
|
10.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2005-0215, U01CA062461, P30CA016672, MDA-2005-0215, NCI-7149, CDR0000480157, 7149, NCT00349206
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 06-365, NCT00483262
|
|
12.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N078D, N078D, NCT00787969
|
|
13.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CASE7808, NCI-2010-00308, CASE7808-CC527, NCT01083368
|
|
14.
|
Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: HCC022, NCT01251458
|
|
15.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-000606401, GENE-C9940-32, UCLA-CCI-779, W-AR-3066K1-201-US, NCI-G01-1917, NCT00012142
|
|
16.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N997B, N997B, NCT00016328
|
|
17.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000068820, U01CA063265, P30CA033572, CHNMC-PHII-27, CHNMC-IRB-99167, NCI-29, 29, NCT00022464
|
|
18.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0186, N0186, NCT00033267
|
|
19.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CWRU-080234, CWRU-WAGM01102, WYETH-C-3066A1-204-WW, NCT00061971
|
|
20.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000331979, UCLA-0306091, WYETH-C-3066A1-132-US, NCT00071968
|
|
21.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-2003-0530, NCI-6182, NCT00075647, 6182
|
|
22.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0323, N0323, NCT00079235
|
|
23.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: OSU-0347, NCI-6186, OSU-2003C0090, 6186, NCT00079456
|
|
24.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCCRC-12983A, NCI-6199, 6199, NCT00084474
|
|
25.
|
Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: MDA-2003-0830, 6178, NCI-6178, NCT00084916
|